Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with diffcult-to-treat CD being cared for at clinical centers across Italy.
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease
Balestrieri, Paola;
2024-01-01
Abstract
Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with diffcult-to-treat CD being cared for at clinical centers across Italy.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
otae060.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
413.19 kB
Formato
Adobe PDF
|
413.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
